Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CERC NASDAQ:GLTO NASDAQ:HOOK NASDAQ:ORMP NASDAQ:OVID On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCERCCerecor$4.78-2.4%$2.60$1.98▼$4.50$458.92M1.441.27 million shs40,370 shsGLTOGalecto$3.53+1.6%$3.19$2.01▼$16.07$4.67M1.3585,854 shs48,726 shsHOOKHOOKIPA Pharma$1.19-3.3%$1.41$0.72▼$6.69$14.50M0.8981,794 shs46,763 shsORMPOramed Pharmaceuticals$2.13+0.5%$2.19$1.82▼$3.09$87.22M1.59141,503 shs18,717 shsOVIDOvid Therapeutics$0.41-3.3%$0.31$0.24▼$1.47$28.80M0.13447,637 shs584,241 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCERCCerecor-2.45%-3.63%+1.49%-2.45%-62.83%GLTOGalecto0.00%+2.20%+5.25%+51.98%-71.85%HOOKHOOKIPA Pharma0.00%-5.93%-16.20%+56.58%-78.36%ORMPOramed Pharmaceuticals0.00%-2.47%-4.91%+0.95%-14.46%OVIDOvid Therapeutics0.00%+17.73%+39.99%+44.64%-53.66%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCERCCerecorN/AN/AN/AN/AN/AN/AN/AN/AGLTOGalecto3.2692 of 5 stars3.55.00.00.01.11.71.3HOOKHOOKIPA Pharma3.0895 of 5 stars3.25.00.00.02.71.70.6ORMPOramed Pharmaceuticals1.0445 of 5 stars0.04.00.00.02.70.80.6OVIDOvid Therapeutics4.7282 of 5 stars3.65.00.04.62.72.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCERCCerecor 0.00N/AN/AN/AGLTOGalecto 3.00Buy$10.00183.61% UpsideHOOKHOOKIPA Pharma 2.33Hold$4.50278.15% UpsideORMPOramed Pharmaceuticals 2.00HoldN/AN/AOVIDOvid Therapeutics 3.20Buy$3.13671.60% UpsideCurrent Analyst Ratings BreakdownLatest ORMP, CERC, OVID, GLTO, and HOOK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025OVIDOvid TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$2.00 ➝ $1.504/24/2025OVIDOvid TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCERCCerecor$6.70M68.50N/AN/A$0.22 per share21.73GLTOGalectoN/AN/AN/AN/A$10.99 per shareN/AHOOKHOOKIPA Pharma$43.95M0.33N/AN/A$4.25 per share0.28ORMPOramed Pharmaceuticals$2M43.51N/AN/A$3.61 per share0.59OVIDOvid Therapeutics$570K50.53N/AN/A$0.96 per share0.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCERCCerecor-$63.50M-$0.57N/AN/AN/A-1,194.82%-261.82%-133.96%N/AGLTOGalecto-$21.44M-$15.53N/AN/AN/AN/A-98.27%-84.29%8/11/2025 (Estimated)HOOKHOOKIPA Pharma-$43.50M-$5.85N/AN/AN/A-785.66%-120.09%-77.14%8/6/2025 (Estimated)ORMPOramed Pharmaceuticals-$19.06M-$0.44N/AN/AN/AN/A-11.34%-10.73%8/13/2025 (Estimated)OVIDOvid Therapeutics-$26.43M-$0.35N/AN/AN/A-4,562.23%-34.17%-25.34%8/12/2025 (Estimated)Latest ORMP, CERC, OVID, GLTO, and HOOK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025HOOKHOOKIPA Pharma-$0.61-$1.23-$0.62-$1.23$3.38 millionN/A5/15/2025Q1 2025ORMPOramed Pharmaceuticals-$0.03-$0.19-$0.16-$0.19N/A$2.00 million5/13/2025Q1 2025OVIDOvid Therapeutics-$0.14-$0.14N/A-$0.14$0.03 million$0.13 million5/8/2025Q1 2025GLTOGalectoN/A-$1.92N/A-$1.92N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCERCCerecorN/AN/AN/AN/AN/AGLTOGalectoN/AN/AN/AN/AN/AHOOKHOOKIPA PharmaN/AN/AN/AN/AN/AORMPOramed PharmaceuticalsN/AN/AN/AN/AN/AOVIDOvid TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCERCCerecor0.792.192.18GLTOGalectoN/A9.629.62HOOKHOOKIPA PharmaN/A3.613.61ORMPOramed PharmaceuticalsN/A23.9423.94OVIDOvid Therapeutics0.224.934.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCERCCerecor62.84%GLTOGalecto14.20%HOOKHOOKIPA Pharma63.88%ORMPOramed Pharmaceuticals12.73%OVIDOvid Therapeutics72.24%Insider OwnershipCompanyInsider OwnershipCERCCerecor45.70%GLTOGalecto10.80%HOOKHOOKIPA Pharma3.30%ORMPOramed Pharmaceuticals13.70%OVIDOvid Therapeutics13.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCERCCerecor3196.01 millionN/ANot OptionableGLTOGalecto401.32 million1.18 millionOptionableHOOKHOOKIPA Pharma16012.19 million11.79 millionOptionableORMPOramed Pharmaceuticals1040.85 million35.25 millionOptionableOVIDOvid Therapeutics6071.11 million61.80 millionOptionableORMP, CERC, OVID, GLTO, and HOOK HeadlinesRecent News About These CompaniesOvid Therapeutics Approves Key Proposals at Annual MeetingJuly 10 at 5:28 PM | tipranks.comOvid Therapeutics Inc. (OVID) - Yahoo FinanceJuly 8, 2025 | finance.yahoo.comOvid Therapeutics Inc Chart - MorningstarJuly 2, 2025 | morningstar.comMJuneberry Farm in Ovid opens for u-pick seasonJuly 1, 2025 | fingerlakes1.comFOvid man, 81, charged with DWI after near-crashJune 28, 2025 | fingerlakes1.comFOvid Therapeutics To Sell Future Royalties Of Ganaxolone For $7 Mln In Cash, Stock Up In Pre-Market - NasdaqJune 27, 2025 | nasdaq.comOvid Therapeutics Sells Ganaxolone Royalty Rights to Immedica Pharma for $7 Million - NasdaqJune 27, 2025 | nasdaq.comOvid Therapeutics Inc.: Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone RoyaltiesJune 25, 2025 | finanznachrichten.deOvid Therapeutics Sells Ganaxolone Royalty Rights to Immedica Pharma for $7 MillionJune 25, 2025 | quiverquant.comQOvid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone RoyaltiesJune 25, 2025 | globenewswire.comAre These 2 'Strong Buy' Rated Growth Stocks Buys Right Now?June 20, 2025 | msn.comOvid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025June 5, 2025 | taiwannews.com.twTOvid Therapeutics Inc. to Host Event on Biomarkers in Epilepsy featuring Dr. Alexander RotenbergJune 5, 2025 | quiverquant.comQOvid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue EstimatesMay 13, 2025 | zacks.comOvid Therapeutics Reports Business Updates and First Quarter 2025 Financial ResultsMay 13, 2025 | globenewswire.comPhoreMost makes key appointments to Board to advance development of next-generation degrader therapeuticsMay 8, 2025 | cambridgenetwork.co.ukCOvid Therapeutics (OVID) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseMay 6, 2025 | zacks.comOvid Police Chief, city accused of civil rights violationsApril 24, 2025 | msn.comOvid Therapeutics (OVID) Receives a Buy from TD CowenApril 23, 2025 | theglobeandmail.comBiotech Leaders Implore Sen. Cassidy To Step Up in Wake of FDA CutsApril 10, 2025 | biospace.comBNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy Quantum Computing Inc. Is the Quiet Winner in Quantum StocksBy Jeffrey Neal Johnson | June 18, 2025View Why Quantum Computing Inc. Is the Quiet Winner in Quantum StocksThe Boring Is Beautiful Portfolio: 3 Stocks for a Worried WorldBy Jeffrey Neal Johnson | June 22, 2025View The Boring Is Beautiful Portfolio: 3 Stocks for a Worried WorldSoundHound Rises as Short Sellers Exit and AI Demand GrowsBy Thomas Hughes | July 9, 2025View SoundHound Rises as Short Sellers Exit and AI Demand GrowsThe Meteoric Rise of Rocket Lab: A Space Stock to WatchBy Ryan Hasson | July 11, 2025View The Meteoric Rise of Rocket Lab: A Space Stock to WatchAstera Labs: AI Infrastructure Play With Significant Growth AheadBy Nathan Reiff | June 26, 2025View Astera Labs: AI Infrastructure Play With Significant Growth AheadORMP, CERC, OVID, GLTO, and HOOK Company DescriptionsCerecor NASDAQ:CERCCerecor, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.Galecto NASDAQ:GLTO$3.53 +0.06 (+1.61%) Closing price 07/11/2025 03:55 PM EasternExtended Trading$3.52 0.00 (-0.03%) As of 07/11/2025 06:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.HOOKIPA Pharma NASDAQ:HOOK$1.19 -0.04 (-3.25%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$1.14 -0.04 (-3.78%) As of 07/11/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.Oramed Pharmaceuticals NASDAQ:ORMP$2.13 +0.01 (+0.47%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$2.13 +0.00 (+0.23%) As of 07/11/2025 04:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.Ovid Therapeutics NASDAQ:OVID$0.40 -0.01 (-3.34%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$0.41 +0.01 (+1.98%) As of 07/11/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/07 - 07/11 Power Solutions International Poised for 75% Upside The Meteoric Rise of Rocket Lab: A Space Stock to Watch Meta and Autonomous Advertising: The Stock's Next Big Tailwind? Super Micro Computer: The Hidden Winner of Soaring Copper Tariffs Nebius Group: Up 385%, Analysts Say It’s Still a Bargain Broadcom Stock: HSBC Sets $400 Target on AI Growth Potential BigBear.ai: Why a 90% Rally Could Be Just the Start Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
